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ABSTRACT
SK Channel Modulators as Drug Candidates
and Pharmacological Tools
by Razan Saud Orfali
The small- and intermediate-conductance Ca2+-activated K+ (SK/IK) channels play a
fundamental role in the regulation of neurons in the central nervous system. In animal
models, SK/IK channel positive modulators have been shown to be effective in
reducing the symptoms of neurological diseases such as ataxia. Ataxia is a lethal
neurological rare disease characterized by lack of balance and incoordination of
muscle movements, often as a result of cerebellar or spinocerebellar
neurodegeneration. SK/IK channel modulators have been developed over the past few
decades. Currently available modulators are often weak in potency. Lack of
knowledge about the binding site for the compounds is the main reason hindering the
development of more potent and effective therapeutics targeting SK channels. Dr.
Zhang and his colleagues recently discovered the binding pocket for these positive
modulators of SK/IK channels. This pocket is located at the interface between the
channel and calmodulin. Dr. Zhang and his colleagues performed screening of a large
number of compounds in silico, to find those fitting into the binding pocket. I
performed electrophysiological recordings to evaluate the efficacy and the potency of
these modulators on SK2 channels. We discovered a correlation between the total
binding energy values calculated from the structures and the potencies determined
from electrophysiological recording.
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CHAPTER 1

INTRODUCTION
1.1 Ataxia
Ataxia, a Greek word that means ‘loss of order,’ is used medically to describe a
devastating neurological disorder characterized by lack of muscle control during
voluntary movements, difficulties with gait, problems with clarity of speech, and
intention tremor, often as a result of cerebellar or spinocerebellar neurodegeneration
(Carlson et al., 2009). The cause of such neurodegeneration can be from brain tumor,
multiple sclerosis, alcoholism or a congenital genetic defect (Carlson et al., 2009;
Matilla-Dueñas et al., 2010; Orr, 2012). There are more than fifty different types of
hereditary ataxias taking place during childhood or adulthood. Most of ataxias
progress over a number of years, and the patients eventually lose the ability to swallow
and breathe smoothly, which can be fatal. The most common type of ataxia is a
cerebellar ataxia that is caused by a dysfunction of the cerebellum or in one of its
pathways. Spinocerebellar ataxia (SCA) is an inherited form of ataxia in an autosomaldominant pattern. SCA is caused by irregular function of the spinocerebellum, the
portion of the cerebellar cortex that receives somatosensory signals from the spinal
cord (Orr, 2012; Orr and Zoghbi, 2007). Currently, twenty-eight autosomal dominant
SCAs have been described (Matilla-Dueñas et al., 2010). The autosomal dominant
SCAs are typically progressive, late-onset, and often lethal neurodegenerative
illnesses.
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1.2 Treatment of Ataxia
There is no cure that can specifically treat ataxia or the symptoms of ataxias.
However, understanding the disease can be helpful to treat, cure, or prevent it. The
cerebellum coordinates motor movement and helps maintain balance and posture. It
has three deep nuclei that provide the main output of the cerebellum. In
neurodegenerative ataxias, neuronal death usually occurs as a result of prolonged
period of neuronal dysfunction (Shakkottai et al., 2011). The cerebellar Purkinje cells
(PCs) are affected in many types of ataxias (Carlson et al., 2009; Orr, 2012; Shakkottai
et al., 2004). PCs are the only output source of cerebellar cortex, and they primarily
promote inhibitory signals to the deep cerebellar nuclei (DCN). The dysfunction of
pacemaking activity in PCs is one of the primary causes for the symptom of early
stage ataxia (Kasumu et al., 2012b; Shakkottai et al., 2011). As this malfunction of
PCs would be expected to cause DCN hyperexcitability. The modulation of the DCN
firing rate by PC input is believed to be responsible for coordination of movement.
Therefore, a direct relationship between increased DCN firing rate and ataxia can be
concluded (Shakkottai et al., 2004). Disruptions of regular cerebellar PCs activities
have been identified in studies with mouse models of Episodic Ataxia EA2 (Walter et
al., 2006), Cerebellar Ataxia (Gao et al., 2012), Spinocerebellar Ataxia SCA3
(Shakkottai et al., 2011) and SCA2 (Kasumu et al., 2012b). However, cerebellar ataxia
could be caused without disturbance of PCs output. One approach to increase the
firing rate of the DCN is to selectively block the SK channels. Cerebellar ataxias were
observed in a transgenic (Tg) mice that expressed a dominant negative isoform of SK
channel (Shakkottai et al., 2004). Hence, in cerebellar ataxias, the pharmacological
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activation of SK channel can serve neuroprotective roles (Hosy et al., 2011). Here,
using electrophysiology, the potency of two positive modulators on the SK2 channels
was demonstrated.
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CHAPTER 2

REVIEW OF LITERATURE
2.1 Overview
Ion channels are the essential elements of the excitable cells that are responsible
for the electrical signaling in nerves, muscles, and synapses. They are macromolecular
pores that conduct and carry ions through the cell membrane. These channels open or
close their pores to permit or block the ion flow in response to extracellular stimuli
such as a membrane potential change (Wei and Lee, 2006).
2.2 Small conductance Ca2+-activated potassium SK channels
Ataxias are often disabling with no symptomatic therapy available.
Consequently, it seems appropriate to search for more effective approaches. The
dysfunction of PCs leads to hyperexcitability of the Deep Cerebellar Nuclei (DCN),
which results in cerebellar ataxia. The SK channels are a unique group of potassium
ion channels that are activated by intracellular Ca2+ ions (Stocker, 2004;
Kovalevskaya et al., 2013). Potassium efflux through these channels modulates cell
excitability. Thus, SK channels have been recognized as potential therapeutic drug
targets for ataxia. SK channels have tetrameric architecture, and each channel subunit
is consisted of six transmembrane α-helical domains (Zhang et al., 2013). Ca2+ binds
to the calcium sensor calmodulin (CaM). Calcium binding to calmodulin prompts
conformational changes in the channel resulting in channel opening. SK channels are
so called because of their small single-channel conductance, whereas the IK channel
has an intermediate single-channel conductance and is thus named an ‘intermediate-
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conductance' channel. SK1, SK2 and SK3, are the three types of SK channels that are
expressed in the neurons, and their activation is involved in afterhyperpolarization that
regulates the firing frequency of action potentials for many types of neurons (Sailer et
al., 2004). SK channels emerged as one of the principle ion channels involved in the
pacemaking of PCs. Among the three subtypes of SK channels, SK2 is the
predominant subtype expressed in PCs (Cingolani et al., 2002; Sailer et al., 2004).
2.3 SK Channels Positive modulators (PAM)
Over the past decade, a significant number of compounds have been developed
targeting SK/IK channels. 1-EBIO (1-ethyl-2-benzimidazolinone), the first positive
modulator was identified twenty years ago, potentiates SK/IK channel activity, and
modulates neuronal excitability (Devor et al., 1996). DCEBIO was developed from
structural optimization of 1-EBIO, and it has about twenty-fold higher potency than 1EBIO (Cui et al., 2014). NeuroSearch A/S, a Scandinavian biopharmaceutical
company has developed a relatively potent IK/SK channels positive modulator NS309
(3-oxime-6,7-dichloro-1H-indole-2,3-dione) (Strøbaek et al., 2004). 1-EBIO and
NS309 are non-selective positive modulators. These modulators cannot activate the
SK/IK channels without the presence of Ca2+. Accordingly, they are termed as SK/IK
channel positive modulators because they enhance the Ca2+ sensitivity of the SK/IK
channels. Despite this progress, many modulators often suffer from low potency
(Pedarzani and Stocker, 2008). Limited knowledge about the binding site for the
compounds reflected in delaying the development of more effective agents targeting
SK channels.
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2.4 The Binding Pocket
A binding pocket exists for SK channels positive modulators at the SK channel/CaM
interface. Dr. Zhang and his colleagues discovered this binding site several years
ago(Zhang et al., 2012). Two FDA approved SK modulators (Chlorzoxazone and
Riluzole) in addition to bound in Calmodulin DCEBIO also shared the same binding
pocket in SK channels. Channel amino acid residues A477 and L480 interact with the
modulators (fig.1A). Fig.1B shows a three-dimensional structure of calmodulin
binding domain (CaMBD) and CaM in complex with riluzole. Calmodulin binding
domain strongly interacts with N-lobe of calmodulin. Also, two calcium ions were Nlobe. The protein structure from SK2 fragment complexed with NS309 (PDB: 4J9Z)
which we determined previously can be used as the model for search of potent SK2
channel modulators (Cui et al., 2014). Significantly, positive modulators have been
shown to share the same binding site at the CaM/CaMBD interface with different
potency, including 1-EBIO and NS309 (fig. 1). A structured analysis of the
CaM/CaMBD complexed with various compounds could be used to facilitate drug
discovery targeting SK channels. The determination of potency of some known PAMs
is described in fig.2.
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Figure 1. Shared binding pocket by DCEBIO. (A), Chlorzoxazone (B) and Riluzole
(C) in the CaM (cyan) complex with SK2-a channel (salmon). (D) Overlay of the
conformations of three compounds obtained from their respective protein crystal
structures. (E) A space-filled model of the CaMBD and CaM in complex with Riluzole.
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Figure 2. Structural basis for determining the potency of known SK modulators.
(A) The interaction energy with major residues in the binding pocket for 1-EBIO,
DCEBIO and NS309. (B) Lack of the hydrogen bonds between 1-EBIO (gray) and the
receptor (magenta). (C) Formation of one hydrogen bond (yellow dash lines) between
DCEBIO (gray) and M51 (cyan). (D) Formation of three hydrogen bonds (yellow dash
lines) between NS309 (gray) and A477, M51 and K75 (yellow).
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CHAPTER 3

METHODOLOGY

The identification of potent and selective SK modulators could alleviate the
symptom of ataxia, in addition to providing pharmacological tools to probe the
important roles of SK channels in the pacemaking of cerebellar PCs during the
development of ataxia. The computer-based approach is able to screen a large number
of compounds in silico, to find those fitting into the binding pocket. Electrophysiology
expertise would be critical in characterizing the new modulators in detail.
3.1 Virtual High Throughput Screening (vHTS) for SK channel modulators.
The protein structure from SK2-a fragment complexed with NS309 (PDB:
4J9Z) determined previously was used as the model for search of novel SK2 channel
modulators. The vHTS screening was performed by Dr. Meng Cui in Northeastern
University School of Pharmacy. The binding pocket of compounds 11 and 14 were
determined by Dr. Young Woo Nam. The interaction energy (Eint) was calculated from
the crystal structures by Dr. Cui in Northeastern University School of Pharmacy.
3.2 Electrophysiology:
SK2 channels were expressed in HEK293 cells. A calcium phosphate method
was used for co-transfection of rat SK2 cDNA in pIRES2-AcGFP1 vector, together
with rat CaM cDNA in pcDNA3.1(+) vector. Channel activities were recorded from
GFP positive cells 1-2 days after transfection (figure.3-A).
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Patch clamp experiments were performed with a Multiclamp Axon 200B
amplifier (Molecular Devices) at room temperature. pClamp 10.6.2 (Molecular
Devices) was used for data analysis and acquisitions. The resistance of the patch
electrodes ranged from 3–7 MΩ. The pipette solution contained 140 mM KCl, 10 mM
HEPES, 1 mM MgSO4, at pH 7.4. The bath solution contained 140 mM KCl and 10
mM HEPES, at pH 7.2. EGTA (1 mM) and HEDTA (1 mM) were mixed with Ca2+ to
obtain free Ca2+ of indicated concentrations, calculated using the software by Chris
Patton of Stanford University (http://www.stanford.edu/~cpatton/maxc.html)
Currents were recorded using an inside-out patch configuration. The
intracellular face was initially exposed to a zero-Ca2+ bath solution, and subsequently
to bath solutions with increasing 0.1 µM Ca2+. Currents were recorded by repetitive 1
sec-voltage ramps from -100 mV to +100 mV from a holding potential of 0mV. One
minute after switch bath solutions, ten sweeps, with a one-second interval, were
recorded at each compound concentration in the presence of 0.1 µM Ca2+. The
integrity of the patch was examined by switching the bath solution back to the zeroCa2+ buffer.
3.3 Data analysis:
To construct the dose–response curve, the current amplitudes were normalized at
maximal concentration. The normalized currents were plotted as a function of the
concentrations of each compound. Relative currents at -100 mV were plotted as a
function of compound concentrations. Half-activation compound concentration (EC50)
and Hill coefficients were determined by fitting the data points obtained from
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individual experiments to a standard dose-response curve (y = 100/(1 + (x/EC50)^Hill)).
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Figure 3. The general principle of patch-clamp electrophysiological recording
technique. (A) SK2 channels were

co-transfected with a Green Fluorescent

Protein (GFP) in HEK293 cells. (B) Diagram illustrating the methods of performing
electrophysiological recordings with the inside-out configuration.
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Figure 4. Diagram illustrating the method of testing compounds using the
electrophysiological recordings. (A) The cells and the pipette under the microscope.
(B) The intracellular side of the channel is exposed to drug in different concentrations
applied to the bath.
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CHAPTER 4

RESULTS AND DISCUSSION

4.1 Activation of SK2 channels by Ca2+
Dose dependent activation of SK2 channels by Ca2+ was measured first. The
raw current traces are indicated in fig. 5A. The threshold Ca2+ concentration was
determined to be 0.1 µM as shown in fig.5B. This threshold Ca2+ concentration is a
minimal concentration of Ca2+ that is required for the modulators. As such, all
following experiments were performed in the presence of 0.1 µ M Ca2+.

4.2 Potentiation of SK2 channels by Compounds #11 and #14
Before I started in the lab, Dr. Cui in Northeastern University has performed
the vHTS, Dr. Zhang and other lab members has purchased and screened the top 100
hit compounds from the vHTS. Dr. Zhang and other lab members has identified
compound #11 and compound #14 as two novel SK channel positive modulators.
After I started in the lab, in order to determine the dose dependent potentiation
of SK2 channels by these compounds, SK2 channels were expressed in HEK293 cells,
and their responses to compound #11 and compound #14 were recorded in the
presence of 0.1 µM Ca2+ in the bath solution.
4.3 Compound #11
SK2 channels showed very minimal activation upon application of a 0.1 µM Ca2+
solution (Fig. 6B). The channel activity was potentiated by compound #11 with
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increasing concentrations, from 0.3 µM up to 300 µM. The maximal response to 300
µM of compound 11 in the presence of 0.1 µM Ca2+ is 94.60 ± 3.03% of the maximal
current induced by µM Ca2+ (Fig. 7). Compound 11 dose dependently potentiate the
SK2 channel activity (Fig. 7A), with the EC50 of 3.87±0.88µM (Fig. 7B) and a Hill
coefficient of 1.40±0.14 (n=8).
4.4 Compound #14
SK2 channels opened slightly upon application of a 0.1 µM Ca2+ solution (Fig. 6C).
The channel activity is further potentiated by compound #14 with increasing
concentrations, from 3µM up to 600 µM. In the presence of 0.1 µM Ca2+, the maximal
response to 600 µM of compound 14 is 92.03± 3.44% of the maximal current induced
by µM Ca2+ (Fig. 7). Compound 14 dose dependently potentiate the SK2 channel
activity (Fig. 7A), with the EC50 of 33.24±4.80µM (Fig. 7B) and a Hill coefficient of
1.40±0.15 (n=9).
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Figure 5. Activation of SK2 channels by Ca2+. (A) Raw current traces from an
inside-out patch with SK2 channels expressed in HEK293 cells. The SK2 channels are
activated by the Ca2+ concentrations indicated. A voltage ramp from −100 mV to
+100 mV was applied. (B) Dose dependent activation of SK2 channels by Ca2+.
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Figure 6. Potentiation of SK2 channel currents by positive allosteric modulators.
(A) The chemical structures of NS309, 1-EBIO, SKS-11 and SKS-14. (B) Raw current
traces from an inside-out patch with SK2 channels expressed in HEK293 cells. The SK2
channels are activated by 0.1µM Ca2+, with subsequent potentiation by compound 11 at
the concentrations indicated (all in the presence of 0.1 µM Ca2+). A voltage ramp, from
−100 mV to +100 mV, was applied. (C) Raw current traces from an inside-out patch
with SK2 channels expressed. The SK2 channels are activated by 0.1 µM Ca2+, with
subsequent potentiation by compound 14 at the concentrations indicated (Nam et al.,
2017).
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Figure 7. Potency of allosteric modulators. (A) Dose–response curves for 1-EBIO,
compound 11, compound 14 and NS309 for their potentiation of the SK2 channel
activities. (B) EC50s of the potentiation of SK2 channel activities by 1-EBIO (n=6),
compound 11(n=8), compound 14(n=9) and NS309(n=8). Note that the y axis is in the
log scale.
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4.5 The correlation between the interaction energy and the potency
Previously, Dr. Zhang’s lab has determined the potency of other known SK channel
modulators, such as 1-EBIO (EC50= 285.99 ± 31.57μM, n=6), and NS309 (EC50=
0.55±0.08μM, n=8). As such, we have four compounds with very diverse potency
values on potentiating SK2 channels including 1-EBIO, compound 14, compound 11
and NS309, in the order of potency from low to high.
Previously, Dr. Zhang has determined the crystal structures of the binding pocket of 1EBIO (PDB: 4G28) and NS309 (PDB: 4J9Z). Recently, Dr. Young Woo Nam in
Zhang Lab determined the crystal structures of the binding pocket of compound 11
and 14 (data not shown). As such, our lab has four crystal structures available for the
binding pocket of the four compounds mentioned above. Our collaborator, Dr. Cui in
Northeastern University calculated the interaction energy between the individual
compound with its binding pocket from these four crystal structures using the
Discovery Studio program.
The correlation between the total interaction energy and the potency of these four
compounds were shown in (Fig. 8). There is a strong correlation between these two
with a correlation coefficient of ~0.99. The correlation remains between the
electrostatic interaction energy and the potency of the compounds (fig. 9A), with a
correlation coefficient of ~0.91. However, the correlation is lost between the van der
Waals (VDW) interaction energy and the potency of the compounds (fig. 9B), with a
correlation coefficient of ~0.74.
Despite the difference in the potency of the compounds, the efficacy of the compounds
in potentiating SK2 channels are not significantly different from each other (fig. 10).
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Figure 8. The Correlation between the interaction energy values with the EC50
values. The x-axis shows total interaction energy of each individual compound (1EBIO, compound 11, compound 14 and NS309) with its binding pocket. The y-axis
shows the potency (EC50 values) of the same group of compounds in potentiation of
SK2 channels. The correlation coefficient is 0.99 (Nam et al., 2017).
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Figure 9. Eint between the compounds and their binding pocket (A) The correlation
between the electrostatic Eint and the potency of NS309, SKS-11, SKS-14 and 1-EBIO
(r = 0.91). (B) The lack of correlation between the VDW Eint and the potency of NS309,
SKS-11, SKS-14 and 1-EBIO (r = 0.74). In (b,c and d), the y-axis is set in log-10 scale
(Nam et al., 2017).
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CHAPTER 5

CONCLUSION

The cerebellum plays an important role in motor control. Cerebellar PCs are
affected in many types of ataxia. The early symptoms of ataxia may result from the
dysfunction of PCs, and loss of firing precision. Based on these findings, drugs that
restore the regular firing of PCs have been suggested as therapeutics for the symptom
of ataxia patients. There are various ion channels that control the spontaneous
electrical activity of PCs. SK channels emerged as one of the principle ion channels
involved in the pacemaking of PCs (Womack and Khodakhah, 2003). SK2 is the
predominant subtype expressed in PCs. SK channels modulate the
afterhyperpolarization of the PCs that occurs after action potential generation.
Therefore, SK channel positive modulators can be effective in alleviating some
behavioral and neuropathological symptoms of ataxia in animal models (Shakkottai et
al., 2011; Walter et al., 2006; Shakkottai et al., 2004; Kasumu et al., 2012a). Several
small molecule modulators of SK channels have been identified previously. Riluzole,
an SK channel modulator, yielded promising results in a phase II clinical trial of a
mixed population of ataxic patients (Ristori et al., 2010). Despite these promising
results, the potency of both agents is not satisfactory for widespread clinical
application.
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The SK channel activator 1-EBIO has low potency, whereas NS309 is a potent SK
channel modulator (Fig. 7A). Compound #11 and compound #14 were identified as
positive modulators of SK2 channels. The purpose of this study is to characterize the
modulators #11 and #14 in details. To achieve this goal, an inside-out patch method
was used to record the currents as the inside surface of the SK2 channel was exposed
to different drug concentrations applied to the bath. Compound #11 was applied in the
range from 0.3 μM to 300 μM to the inside of the patch at a [Ca2+] of 0.1 μM resulted
in a concentration-dependent potentiation of the SK2 current (Figure 6B). To quantify
the dose dependence of compound #11, a number of experiments were performed and
the current response in each experiment was normalized. The normalized data were
averaged and plotted together with other positive modulators (fig 7A). Data were fitted
by the Hill equation which yielded an EC50 value for SK2 potentiation of
3.87±0.88µM, a Hill coefficient of 1.40±0.14 (n=8) of compound #11. Figure. 7A
depicts that compound #11 potently activated SK2 channels more than compound #14.
Moreover, The EC50 of compound is less than the EC50 of compound #14. The EC50
indicates how much of the agent is needed to achieve the half-maximal response. The
potency of the compound is inversely related to the EC50. The more potent the agent
the smaller the EC50 will be. Thus, compound # 11 can be considered as a highly
potent SK channel modulator, but when compared to NS309, compound # 11 is less
potent than the most potent modulator, NS309. Using electrophysiology, I evaluated
the efficacy and potency of two positive modulators (compounds 11 and 14) on the
SK2 channels. The efficacy values of these two compounds are not significantly
different from the efficacy of 1-EBIO and NS309 as reported previously by Dr. Zhang
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(Fig. 10), whereas the potency values of 1-EBIO, compound 14, compound 11 and
NS309 are significantly different from each other (Fig. 7B). Utilizing the previous
data from Dr. Zhang on the potency of two other modulators (1-EBIO and NS309) and
the crystal structures of the binding pocket of the compounds determined by Dr. Nam,
I found a correlation between the potency of these compounds and the interaction
energy of the compounds to their binding pocket (fig. 8). These structure-activity
relationship studies will provide valuable information on how the potency of the
compounds can be improved through chemical modification, which will facilitate drug
discovery targeting SK channels to combat ataxia. The results described in this thesis
have been published in the Scientific Report journal on December 7, 2017 (Nam et
al., 2017).
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Figure 10. Efficacy of the compounds. The maximal response of the compounds is
normalized to the maximal response of 10 µM Ca2+. Efficacy induced by 1-EBIO(n=6),
compound 11(n=8), compound 14(n=9) and NS309(n=8).
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